AAPL346.47-1.76 (-0.50%) ▼|ABBV286.27+1.08 (+0.38%) ▲|ABT103.39+0.88 (+0.85%) ▲|ACN246.85-11.89 (-4.60%) ▼|ADBE265.46-5.09 (-1.88%) ▼|AMAT379.68+4.10 (+1.09%) ▲|AMD517.55+9.62 (+1.89%) ▲|AMGN440.79-6.50 (-1.45%) ▼|AMT188.31+6.74 (+3.71%) ▲|AMZN248.72-1.66 (-0.66%) ▼|AVGO324.44+1.20 (+0.37%) ▲|AXP313.19-11.99 (-3.69%) ▼|BA188.39+0.84 (+0.45%) ▲|BAC50.69-0.39 (-0.76%) ▼|BKNG157.14-3.96 (-2.46%) ▼|BLK1,113.83-23.46 (-2.06%) ▼|BMY61.60-1.41 (-2.23%) ▼|BNY145.18-0.14 (-0.10%) ▼|BRK-B541.26-5.72 (-1.04%) ▼|C120.98-1.53 (-1.25%) ▼|CAT687.03-17.02 (-2.42%) ▼|CL93.96-3.44 (-3.53%) ▼|CMCSA22.79-0.06 (-0.24%) ▼|COF200.41-3.03 (-1.49%) ▼|COP151.55+5.92 (+4.06%) ▲|COST1,005.69-12.53 (-1.23%) ▼|CRM248.53-1.76 (-0.70%) ▼|CSCO106.27+1.38 (+1.31%) ▲|CVS93.49-0.99 (-1.05%) ▼|CVX232.73+6.05 (+2.67%) ▲|DE644.45+0.83 (+0.13%) ▲|DHR227.11-2.64 (-1.15%) ▼|DIS112.83-0.30 (-0.27%) ▼|DUK124.62-0.78 (-0.62%) ▼|EMR162.15+1.86 (+1.16%) ▲|FDX299.08-4.84 (-1.59%) ▼|GD350.40-0.39 (-0.11%) ▼|GE287.94-5.60 (-1.91%) ▼|GEV825.89-1.53 (-0.18%) ▼|GILD156.61-0.58 (-0.37%) ▼|GM75.84-1.38 (-1.78%) ▼|GOOG319.00-1.76 (-0.55%) ▼|GOOGL322.04-2.18 (-0.67%) ▼|GS882.67-8.63 (-0.97%) ▼|HD318.43-9.30 (-2.84%) ▼|HON221.41+3.10 (+1.42%) ▲|IBM252.93+0.82 (+0.33%) ▲|INTC86.84+1.35 (+1.57%) ▲|INTU346.15-8.75 (-2.47%) ▼|ISRG453.48+9.63 (+2.17%) ▲|JNJ263.03-4.59 (-1.71%) ▼|JPM332.14-4.41 (-1.31%) ▼|KO92.81-2.54 (-2.66%) ▼|LIN508.28-2.08 (-0.41%) ▼|LLY1,264.74-41.96 (-3.21%) ▼|LMT606.54+16.63 (+2.82%) ▲|LOW198.74-5.63 (-2.75%) ▼|LRCX230.80+0.65 (+0.28%) ▲|MA622.06-11.15 (-1.76%) ▼|MCD247.61-5.02 (-1.99%) ▼|MDLZ63.54-1.65 (-2.53%) ▼|MDT95.87-0.72 (-0.75%) ▼|META644.58-4.28 (-0.66%) ▼|MMM173.96-1.61 (-0.91%) ▼|MO74.46-1.61 (-2.12%) ▼|MRK145.00-2.24 (-1.52%) ▼|MS180.85-3.12 (-1.70%) ▼|MSFT524.59+3.51 (+0.67%) ▲|MU883.15+26.66 (+3.11%) ▲|NEE81.71-0.19 (-0.23%) ▼|NFLX66.12-0.93 (-1.39%) ▼|NKE37.48-0.85 (-2.21%) ▼|NOW158.45+1.45 (+0.92%) ▲|NVDA211.67-0.54 (-0.25%) ▼|ORCL127.74+2.20 (+1.75%) ▲|PEP135.50-3.34 (-2.40%) ▼|PFE30.04-0.38 (-1.25%) ▼|PG161.31-3.19 (-1.94%) ▼|PLTR196.12-0.08 (-0.04%) ▼|PM199.53-2.21 (-1.10%) ▼|QCOM174.94+2.11 (+1.22%) ▲|RTX191.65-3.07 (-1.57%) ▼|SBUX100.70-1.21 (-1.19%) ▼|SCHW90.45-0.99 (-1.08%) ▼|SO92.91-0.92 (-0.98%) ▼|SPG210.98-1.06 (-0.50%) ▼|T21.23-1.52 (-6.66%) ▼|TMO670.40-6.14 (-0.91%) ▼|TMUS148.89-9.90 (-6.23%) ▼|TSLA372.06-2.52 (-0.67%) ▼|TXN284.60+5.10 (+1.82%) ▲|UBER67.21-1.87 (-2.70%) ▼|UNH417.92-7.07 (-1.66%) ▼|UNP294.02-4.07 (-1.37%) ▼|UPS101.29-0.23 (-0.23%) ▼|USB59.61-0.41 (-0.68%) ▼|V409.13-5.21 (-1.26%) ▼|VZ44.46-0.74 (-1.64%) ▼|WFC82.36-0.66 (-0.79%) ▼|WMT119.41-1.71 (-1.41%) ▼|XOM182.62+4.39 (+2.46%) ▲|AAPL346.47-1.76 (-0.50%) ▼|ABBV286.27+1.08 (+0.38%) ▲|ABT103.39+0.88 (+0.85%) ▲|ACN246.85-11.89 (-4.60%) ▼|ADBE265.46-5.09 (-1.88%) ▼|AMAT379.68+4.10 (+1.09%) ▲|AMD517.55+9.62 (+1.89%) ▲|AMGN440.79-6.50 (-1.45%) ▼|AMT188.31+6.74 (+3.71%) ▲|AMZN248.72-1.66 (-0.66%) ▼|AVGO324.44+1.20 (+0.37%) ▲|AXP313.19-11.99 (-3.69%) ▼|BA188.39+0.84 (+0.45%) ▲|BAC50.69-0.39 (-0.76%) ▼|BKNG157.14-3.96 (-2.46%) ▼|BLK1,113.83-23.46 (-2.06%) ▼|BMY61.60-1.41 (-2.23%) ▼|BNY145.18-0.14 (-0.10%) ▼|BRK-B541.26-5.72 (-1.04%) ▼|C120.98-1.53 (-1.25%) ▼|CAT687.03-17.02 (-2.42%) ▼|CL93.96-3.44 (-3.53%) ▼|CMCSA22.79-0.06 (-0.24%) ▼|COF200.41-3.03 (-1.49%) ▼|COP151.55+5.92 (+4.06%) ▲|COST1,005.69-12.53 (-1.23%) ▼|CRM248.53-1.76 (-0.70%) ▼|CSCO106.27+1.38 (+1.31%) ▲|CVS93.49-0.99 (-1.05%) ▼|CVX232.73+6.05 (+2.67%) ▲|DE644.45+0.83 (+0.13%) ▲|DHR227.11-2.64 (-1.15%) ▼|DIS112.83-0.30 (-0.27%) ▼|DUK124.62-0.78 (-0.62%) ▼|EMR162.15+1.86 (+1.16%) ▲|FDX299.08-4.84 (-1.59%) ▼|GD350.40-0.39 (-0.11%) ▼|GE287.94-5.60 (-1.91%) ▼|GEV825.89-1.53 (-0.18%) ▼|GILD156.61-0.58 (-0.37%) ▼|GM75.84-1.38 (-1.78%) ▼|GOOG319.00-1.76 (-0.55%) ▼|GOOGL322.04-2.18 (-0.67%) ▼|GS882.67-8.63 (-0.97%) ▼|HD318.43-9.30 (-2.84%) ▼|HON221.41+3.10 (+1.42%) ▲|IBM252.93+0.82 (+0.33%) ▲|INTC86.84+1.35 (+1.57%) ▲|INTU346.15-8.75 (-2.47%) ▼|ISRG453.48+9.63 (+2.17%) ▲|JNJ263.03-4.59 (-1.71%) ▼|JPM332.14-4.41 (-1.31%) ▼|KO92.81-2.54 (-2.66%) ▼|LIN508.28-2.08 (-0.41%) ▼|LLY1,264.74-41.96 (-3.21%) ▼|LMT606.54+16.63 (+2.82%) ▲|LOW198.74-5.63 (-2.75%) ▼|LRCX230.80+0.65 (+0.28%) ▲|MA622.06-11.15 (-1.76%) ▼|MCD247.61-5.02 (-1.99%) ▼|MDLZ63.54-1.65 (-2.53%) ▼|MDT95.87-0.72 (-0.75%) ▼|META644.58-4.28 (-0.66%) ▼|MMM173.96-1.61 (-0.91%) ▼|MO74.46-1.61 (-2.12%) ▼|MRK145.00-2.24 (-1.52%) ▼|MS180.85-3.12 (-1.70%) ▼|MSFT524.59+3.51 (+0.67%) ▲|MU883.15+26.66 (+3.11%) ▲|NEE81.71-0.19 (-0.23%) ▼|NFLX66.12-0.93 (-1.39%) ▼|NKE37.48-0.85 (-2.21%) ▼|NOW158.45+1.45 (+0.92%) ▲|NVDA211.67-0.54 (-0.25%) ▼|ORCL127.74+2.20 (+1.75%) ▲|PEP135.50-3.34 (-2.40%) ▼|PFE30.04-0.38 (-1.25%) ▼|PG161.31-3.19 (-1.94%) ▼|PLTR196.12-0.08 (-0.04%) ▼|PM199.53-2.21 (-1.10%) ▼|QCOM174.94+2.11 (+1.22%) ▲|RTX191.65-3.07 (-1.57%) ▼|SBUX100.70-1.21 (-1.19%) ▼|SCHW90.45-0.99 (-1.08%) ▼|SO92.91-0.92 (-0.98%) ▼|SPG210.98-1.06 (-0.50%) ▼|T21.23-1.52 (-6.66%) ▼|TMO670.40-6.14 (-0.91%) ▼|TMUS148.89-9.90 (-6.23%) ▼|TSLA372.06-2.52 (-0.67%) ▼|TXN284.60+5.10 (+1.82%) ▲|UBER67.21-1.87 (-2.70%) ▼|UNH417.92-7.07 (-1.66%) ▼|UNP294.02-4.07 (-1.37%) ▼|UPS101.29-0.23 (-0.23%) ▼|USB59.61-0.41 (-0.68%) ▼|V409.13-5.21 (-1.26%) ▼|VZ44.46-0.74 (-1.64%) ▼|WFC82.36-0.66 (-0.79%) ▼|WMT119.41-1.71 (-1.41%) ▼|XOM182.62+4.39 (+2.46%) ▲|
15.7 C
New York
Friday, October 23, 2026

Tag: resistance

newsFORsourcecompanycontentinformation1releasesmarket

Best Delta 8 Gummies of 2025: Area 52 Named #1 Edible by Oregon Observer

While competitors push high-THC options, Area 52’s Delta 8 Gummies lead with a balanced, clear-headed experience—now joined by UFO MAX and UFO in the top 3 
While competitors push high-THC options, Area 52’s Delta 8 Gummies lead with a balanced, clear-headed experience—now joined by UFO MAX and UFO in the top 3

Best THCA Vape of 2025 – Area 52 Named #1 Disposable by Oregon Observer

THCA Vapes Dominate Premium Cannabis Market as Area 52 Named Best THCA Vape of 2025 
THCA Vapes Dominate Premium Cannabis Market as Area 52 Named Best THCA Vape of 2025

RITFIT’s 2025 Strategy: Elevating Home Fitness with Personalized, Professional-Grade Equipment

LOUISVILLE, Ky., July 4, 2025 /PRNewswire/ -- RITFIT, a leading global home fitness brand, has made a groundbreaking announcement at the HomeGymCon 2025, revealing its...

CF & CFRP Market worth $35.55 billion in 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 4, 2025 /PRNewswire/ -- The report "CF & CFRP Market by Precursor Type (PAN, Pitch), Source, Resin Type, Manufacturing Process (Lay-Up,...

CF & CFRP Market worth $35.55 billion in 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 4, 2025 /PRNewswire/ -- The report "CF & CFRP Market by Precursor Type (PAN, Pitch), Source, Resin Type, Manufacturing Process (Lay-Up,...

NAIPO and MaxKare Light Up Walmart Deals Time July 8-13 with Unbeatable Discounts Up to 75% OFF!

Newark, N.J., July 4, 2025 /PRNewswire/ -- This July, Walmart Deals is back — and hotter than ever! From July 8 to 13, get...

AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer

PRESS RELEASE

Strüngmann Award Honors Araris Biotech Founding Team as 2025 Winner

Munich, Germany, July 04, 2025 – The Strüngmann Award selection committee today announced that Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D., the founders of Araris Biotech, have been honored as this year’s winners. The award aims to support outstanding entrepreneurial and scientific achievements, as well as ground-breaking ideas in the life sciences industry. Araris Biotech’s founding team distinguished itself not only by developing of a novel technology in the antibody-drug conjugates (ADCs) field, but also by successfully validating this innovation through partnerships and a preclinical exit. This new drug class has the potential to significantly advance the development of targeted cancer therapies, thereby delivering added value for people living with cancer worldwide.

DELUXE SYSTEMS TO SHOWCASE ICONIC ITALIAN CRAFTSMANSHIP AT ARCHIDEX 2025

From Italy to Malaysia: A Celebration of Design, Precision, and Architectural Elegance KUALA LUMPUR, Malaysia, July 4, 2025 /PRNewswire/ -- Deluxe Systems is proud to...

Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China

Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater ChinaBrii Biosciences retains ex-Greater China rights to address the global antimicrobial...

Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China

Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater ChinaBrii Biosciences retains ex-Greater China rights to address the global antimicrobial...

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on July 1, 2025 (the “Grant Date”), ORIC granted a total of 9,000 non-qualified stock options and 1,600 restricted stock units to one new non-executive employee who began their employment with ORIC in June 2025.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsResistance

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers